Revenue Growth ETST reports revenue of 35.7 million for the fiscal year ended March 31, 2026, up 8% year over year with a gross profit of 25.5 million and net income of 3.6 million, signaling improving profitability and potential for scale in nutraceuticals and cosmeceuticals.

Product Diversification The company focuses on nutraceuticals, bioceuticals, phytoceuticals, and cosmeceuticals across health, wellness, and alternative medicine markets, presenting cross-sell opportunities for bundled formulations and white-label partnerships.

Telehealth Expansion Launch of MyOnlineConsultation.com through MOCTeledoc LLC creates B2B and B2C channels for remote physician networks, enabling potential collaborations in telehealth-enabled supplement programs and physician-guided regimens.

Public Market Presence Publicly traded status (OTC ETST) with investor conference activity, including Planet MicroCap Las Vegas 2026, suggests opportunities for investor-focused outreach, strategic partnerships, and credibility to accelerate channel partnerships.

Strategic Growth Initiatives Recent acquisitions and brand launches such as Zoolzy under Peaks Curative, along with leadership appointments like a new CTO in 2024, indicate a proactive strategy to expand IP, product lines, and technology capabilities that can be leveraged for new distribution and contract manufacturers.